Follow The Filings

DARE Dare Bioscience

Dare Bioscience earnings company data as of 4:48 AM ET 10/23

  • 1 of 1 EPS beats

History

2 periods, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 12 Nov EPS — — —
Rev — — —
FY2026 Q2 13 Aug EPS -0.30 -0.20 Beat
Rev — $200.0K —

Insider trades

Open-market buys and sales by DARE's executives, directors and 10% owners in the last 12 months, from their Form 4s

All DARE insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales

No open-market buys or sales on file.

Also filed in the last 12 months, not counted as buying or selling: 5 stock grants.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
DEF 14A
8-K 3.01
8-K 7.01,9.01
8-K 5.03
8-K 7.01,9.01
424B3
SCHEDULE 13G —
S-1
SCHEDULE 13G —
424B5
8-K 1.01,3.02,8.01,9.01
10-Q
8-K 2.02,9.01
8-K 7.01,9.01
8-K 3.01
8-K 7.01,9.01
8-K 7.01,9.01
8-K 5.02,5.07,9.01
DEFA14A
DEFA14A
8-K 3.02
8-K 2.02
10-Q
8-K 3.02
DEF 14A

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.